Aradigm Corp. Company Profile (NASDAQ:ARDM)

About Aradigm Corp.

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Delivery
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: ARDM
CUSIP:

Key Metrics:

Previous Close: $6.25
50 Day Moving Average: $4.77
200 Day Moving Average: $4.52
52-Week Range: $14,781,000.00 - $2.60
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -3.53
P/E Growth: 0.00
Market Cap: $96.08M
Outstanding Shares: 14,781,000
Beta: 0.9

Profitability:

Net Margins: -670.67%
Return on Equity: -147.53%
Return on Assets: -88.51%

Debt:

Debt-to-Equity Ratio: 0.66%
Current Ratio: 6.85%
Quick Ratio: 6.85%

Additional Links:

Companies Related to Aradigm Corp.:

Consensus Ratings for Aradigm Corp. (NASDAQ:ARDM) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Aradigm Corp. (NASDAQ:ARDM)

Show:

No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Aradigm Corp. (NASDAQ:ARDM)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/9/2016
8/10/2016	Q2	($0.59)	($0.59)			View	N/A
5/10/2016	Q1	($0.59)	($0.55)			View	N/A
3/15/2016	Q415	($0.55)	($0.63)			View	N/A
11/11/2015	Q3	($0.19)	($0.38)			View	N/A
8/13/2015	Q2	($0.08)	($0.08)	$11.60 million	$10.00 million	View	N/A
5/11/2015	Q1	($0.06)	($0.08)			View	N/A
3/17/2015	Q414	($0.07)	($0.06)	$6.70 million	$8.10 million	View	N/A
11/7/2014	Q314	($0.10)	($0.06)	$4.80 million	$6.60 million	View	N/A
8/7/2014	Q214	($0.09)	($0.09)	$4.25 million	$12.20 million	View	N/A
10/28/2013	Q3 13		($0.04)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Aradigm Corp. (NASDAQ:ARDM)

Current Year EPS Consensus Estimate: $-1.92 EPS
Next Year EPS Consensus Estimate: $-1.84 EPS

Dividend History for Aradigm Corp. (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aradigm Corp. (NASDAQ:ARDM)

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 44.27%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/21/2016	Juergen Kurt Froehlich	Insider	Sell	333	$4.45	$1,481.85
12/13/2013	Virgil Thompson	Director	Sell	3,340	$0.17	$567.80
8/27/2013	First Eagle Investment Managem	Major Shareholder	Buy	40,322,580	$0.12	$4,838,709.60
12/11/2012	First Eagle Investment Managem	Major Shareholder	Buy	41,666,667	$0.12	$5,000,000.04

(Data available from 1/1/2013 forward)

Latest Headlines for Aradigm Corp. (NASDAQ:ARDM)

Date	Headline
	Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) (NASDAQ:ARDM) www.pharmiweb.com - September 24 at 8:51 AM
	Manufacturing Stocks Review – Winners and Losers (NASDAQ:ARDM) www.fxpips.com - September 23 at 8:24 AM
	ARDM Awaits Data In Q4, FDA Clears TCMD Device, Newfound Interest For GLMD, GALT (NASDAQ:ARDM) www.rttnews.com - September 23 at 8:24 AM
	3 Reasons Why Aradigm Corporation (ARDM) is a Great Momentum Stock (NASDAQ:ARDM) finance.yahoo.com - September 22 at 3:31 PM
	Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin ... (NASDAQ:ARDM) www.biomedreports.com - September 22 at 9:26 AM
	Aradigm Corporation To Present At The 2016 Healthcare Conference On September 27 (NASDAQ:ARDM) www.biospace.com - September 22 at 9:26 AM
	Aradigm (ARDM) Shares March Higher, Can It Continue? (NASDAQ:ARDM) www.nasdaq.com - September 22 at 9:26 AM
	Aradigm Announces Last Patient Dosing Visit in ORBIT-3 & ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchie... (NASDAQ:ARDM) www.advfn.com - September 22 at 9:26 AM
	Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients (NASDAQ:ARDM) www.publicnow.com - September 22 at 9:26 AM
	Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City (NASDAQ:ARDM) www.publicnow.com - September 21 at 8:49 AM
	Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27 (NASDAQ:ARDM) finance.yahoo.com - September 20 at 9:29 AM
	Aradigm Corporation (ARDM) - Medical Equipment - Deals and Alliances Profile - New Market Report (NASDAQ:ARDM) reports.pr-inside.com - September 16 at 3:32 PM
	Newly released market study: Stille AB (STIL) - Medical Equipment - Deals and Alliances Profile (NASDAQ:ARDM) reports.pr-inside.com - September 15 at 12:28 PM
	Aradigm Corp. :ARDM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:ARDM) www.capitalcube.com - August 12 at 12:07 PM
	Aradigm reports 2Q loss (NASDAQ:ARDM) sg.finance.yahoo.com - August 10 at 9:40 AM
	Aradigm Announces Second Quarter 2016 Financial Results (NASDAQ:ARDM) www.publicnow.com - August 10 at 9:40 AM
	ARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ARDM) biz.yahoo.com - June 10 at 5:02 PM
	Aradigm Corp. :ARDM-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:ARDM) www.capitalcube.com - May 17 at 12:15 PM
	Two Presentations on Aradigm's Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference (NASDAQ:ARDM) www.publicnow.com - May 11 at 7:22 AM
	Two Presentations on Aradigm’s Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference (NASDAQ:ARDM) finance.yahoo.com - May 11 at 7:00 AM
	Aradigm reports 1Q loss (NASDAQ:ARDM) sg.finance.yahoo.com - May 10 at 9:03 AM
	Aradigm Announces First Quarter 2016 Financial Results (NASDAQ:ARDM) www.publicnow.com - May 10 at 7:08 AM
	Activist Starboard Value Gets Seats on Marvell Technology Group Ltd. (MRVL)’s Board; Two Other Hedge Funds Disclose Latest Moves (NASDAQ:ARDM) www.insidermonkey.com - April 29 at 9:42 AM
	ARADIGM CORP Files SEC form 8-K/A, Financial Statements and Exhibits (NASDAQ:ARDM) biz.yahoo.com - April 28 at 4:08 PM
	ARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio (NASDAQ:ARDM) biz.yahoo.com - April 27 at 4:30 PM
	Aradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021 (NASDAQ:ARDM) www.publicnow.com - April 26 at 7:26 AM
	ARADIGM CORP Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:ARDM) biz.yahoo.com - April 25 at 12:08 PM
	Slew of results disappointments hamstring S&P (NASDAQ:ARDM) www.proactiveinvestors.co.uk - April 23 at 6:45 AM
	Aradigm Corporation Prices Private Placement of Senior Notes (NASDAQ:ARDM) www.publicnow.com - April 22 at 8:36 AM
	ARADIGM CORP Files SEC form 10-K, Annual Report (NASDAQ:ARDM) biz.yahoo.com - March 30 at 2:33 PM
	7:00 am Aradigm announces that the EMA has approved its request to review Pulmaquin under the Centralised Authorisation Procedure drug review process (NASDAQ:ARDM) finance.yahoo.com - March 17 at 7:00 AM
	Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency (NASDAQ:ARDM) finance.yahoo.com - March 17 at 7:00 AM
	Aradigm reports 4Q loss (NASDAQ:ARDM) sg.finance.yahoo.com - March 15 at 7:13 AM
	Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results (NASDAQ:ARDM) finance.yahoo.com - March 15 at 7:00 AM
	Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8 (NASDAQ:ARDM) finance.yahoo.com - February 2 at 7:00 AM
	Aradigm to Host Corporate Update Conference Call on January 6 (NASDAQ:ARDM) www.noodls.com - January 5 at 7:28 AM
	Aradigm Corp.: Sudden move in price, will it continue? (NASDAQ:ARDM) www.capitalcube.com - December 23 at 5:16 PM
	Aradigm Corp. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:ARDM) www.capitalcube.com - December 21 at 12:11 PM
	ARADIGM CORP Financials (NASDAQ:ARDM) finance.yahoo.com - December 8 at 1:17 PM
	How it All Plays Out - Research on Aradigm, Ideal Power, CareDx, and Colony Bankcorp (NASDAQ:ARDM) finance.yahoo.com - December 3 at 8:40 AM
	ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ARDM) biz.yahoo.com - November 12 at 3:20 PM
	ARADIGM CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:ARDM) biz.yahoo.com - November 12 at 6:12 AM
	Aradigm Announces Third Quarter 2015 Financial Results (NASDAQ:ARDM) www.noodls.com - November 11 at 7:16 AM
	Aradigm reports 3Q loss (NASDAQ:ARDM) sg.finance.yahoo.com - November 11 at 7:06 AM
	Aradigm Corp. – Value Analysis (NASDAQ:ARDM) : October 30, 2015 (NASDAQ:ARDM) www.capitalcube.com - October 30 at 3:19 PM
	Aradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) (NASDAQ:ARDM) finance.yahoo.com - October 13 at 7:00 AM
	Aradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 (NASDAQ:ARDM) www.noodls.com - September 23 at 7:25 AM